Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mobia Medical Q3 2026 Results: Net Loss of $17.3M, Loss Widens

Mobia Medical reported significant revenue growth for the nine months ended September 30, 2026, reaching $41.2 million compared to $21.3 million in the prior year. However, the company remains in a net loss position with an accumulated deficit of $213.9 million, primarily driven by high selling, general, and administrative expenses as it scales operations following its initial public offering.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue15.69.0
Gross profit13.07.2
Profit before tax-17.3-11.4
Net income-17.3-11.4
EPS (diluted, $ a share)$-0.52$-13.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+73.3%
Gross margin83.2%
Operating margin-118.7%
Source

10-Q filed with the SEC, NASDAQ: MOBI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mobia Medical, Inc.: key numbers

Share price
$12.61Close, Nov 17
Market cap
$420M
Shares outstanding
33.33MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mobia Medical, Inc.

All →
4:14 PM ET 8-K
Financial Results

Mobia Medical Financial Results

Mobia Medical reported Q3 2026 revenue of $15.6 million, a 73% year-over-year increase driven by broader adoption of its Vivistim System. The company also raised its full-year 2026 revenue guidance to a range of $57.0 million to $57.5 million, reflecting strong commercial execution and territory expansion.

Term
Q3 2026

“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel.”

Richard Foust, President and Chief Executive Officer

“Additionally, we were pleased to announce the inclusion of paired VNS in the updated AHA Stroke guidelines for 2026, serving as validation of our evidence-based approach to stroke recovery and further recognition of how Vivistim® Paired VNS™ Therapy can redefine what is possible for stroke survivors.”

Richard Foust, President and Chief Executive Officer
4:32 PM ET 8-K/A
Leadership Change

Mobia Medical Leadership Change

Mobia Medical, Inc. appointed Myriam J. Curet, M.D., to its nominating and corporate governance committee, effective October 15, 2026. This filing is an amendment to a previous 8-K to finalize her committee assignment following her earlier election to the Board of Directors.

4:31 PM ET 8-K/A
Leadership Change

Mobia Medical Leadership Change

Mobia Medical, Inc. announced that the Board of Directors appointed Dr. Reza Zadno to its audit committee, effective October 15, 2026. Dr. Zadno, who was previously elected to the Board, will also continue to serve on the company's compensation committee.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.